HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price target.
Verona Pharma Expect To Submit New Drug Application To US FDA In Q2 Of 2023; To Release Additional Information From The Enhance Trials
“2023 is expected to be another pivotal year for Verona Pharma as we continue preparing for the planned commercial launch of ensifentrine in the US in 2024, if approved. We expect to submit a New Drug Application
Verona Pharma Q4 EPS $(0.02) Beats $(0.10) Estimate, Sales $458.00K Miss $3.57M Estimate
Verona Pharma (NASDAQ:VRNA) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.10) by 80 percent. This is a 95 percent increase over losses of $(0.40) per share from the same
PDS Biotechnology, Pulmonx, Tesla And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Nasdaq Composite dropping around 50 points on Tuesday. Here are some big stocks recording losses in today’s session.
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
Verona Pharma (NASDAQ:VRNA) has outperformed the market over the past 5 years by 7.76% on an annualized basis…
12 Health Care Stocks Moving In Wednesday’s Intraday Session
Gainers Venus Concept (NASDAQ:VERO) shares increased by 61.1% to $0.41 during Wednesday’s regular session. Trading volume for this…
Tesla, Amazon, Nike, FedEx, Verona Pharma: Why These 5 Stocks Are Drawing Investors’ Attention Today
Major Wall Street indices closed in the green on Tuesday, albeit just marginally higher, ending a four-day losing streak as investors and traders are watching out for a much anticipated year-end rally. Surprisingly, market partic
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers Athenex (NASDAQ:ATNX) stock moved upwards by 41.4% to $0.19 during Tuesday’s regular session. Trading volume for this…
BTIG Maintains Buy on Verona Pharma, Raises Price Target to $26
BTIG analyst Thomas Shrader maintains Verona Pharma (NASDAQ:VRNA) with a Buy and raises the price target from $17 to $26.
Verona Pharma Stock Garners Investors’ Attention After Successful COPD Trial
Verona Pharma plc (NASDAQ:VRNA) has announced positive results of its Phase 3 ENHANCE-1 trial of nebulized ensifentrine for the maintenance treatment…